These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 26832408)

  • 1. Drosophila Lung Cancer Models Identify Trametinib plus Statin as Candidate Therapeutic.
    Levine BD; Cagan RL
    Cell Rep; 2016 Feb; 14(6):1477-1487. PubMed ID: 26832408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fluvastatin Prevents Lung Adenocarcinoma Bone Metastasis by Triggering Autophagy.
    Yang Z; Su Z; DeWitt JP; Xie L; Chen Y; Li X; Han L; Li D; Xia J; Zhang Y; Yang Y; Jin C; Zhang J; Li S; Li K; Zhang Z; Qu X; He Z; Chen Y; Shen Y; Ren M; Yuan Z
    EBioMedicine; 2017 May; 19():49-59. PubMed ID: 28454732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib.
    Park KS; Oh B; Lee MH; Nam KY; Jin HR; Yang H; Choi J; Kim SW; Lee DH
    Cancer Lett; 2016 Mar; 372(1):75-81. PubMed ID: 26723875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluvastatin and cisplatin demonstrate synergistic cytotoxicity in epithelial ovarian cancer cells.
    Taylor-Harding B; Orsulic S; Karlan BY; Li AJ
    Gynecol Oncol; 2010 Dec; 119(3):549-56. PubMed ID: 20837358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutant LKB1 Confers Enhanced Radiosensitization in Combination with Trametinib in KRAS-Mutant Non-Small Cell Lung Cancer.
    Wang Y; Li N; Jiang W; Deng W; Ye R; Xu C; Qiao Y; Sharma A; Zhang M; Hung MC; Lin SH
    Clin Cancer Res; 2018 Nov; 24(22):5744-5756. PubMed ID: 30068711
    [No Abstract]   [Full Text] [Related]  

  • 6. Trametinib downregulates survivin expression in RB1-positive KRAS-mutant lung adenocarcinoma cells.
    Sumi T; Hirai S; Yamaguchi M; Tanaka Y; Tada M; Niki T; Takahashi H; Sakuma Y
    Biochem Biophys Res Commun; 2018 Jun; 501(1):253-258. PubMed ID: 29727601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coadministration of Trametinib and Palbociclib Radiosensitizes KRAS-Mutant Non-Small Cell Lung Cancers In Vitro and In Vivo.
    Tao Z; Le Blanc JM; Wang C; Zhan T; Zhuang H; Wang P; Yuan Z; Lu B
    Clin Cancer Res; 2016 Jan; 22(1):122-33. PubMed ID: 26728409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MEK inhibitor trametinib does not prevent the growth of anaplastic lymphoma kinase (ALK)-addicted neuroblastomas.
    Umapathy G; Guan J; Gustafsson DE; Javanmardi N; Cervantes-Madrid D; Djos A; Martinsson T; Palmer RH; Hallberg B
    Sci Signal; 2017 Nov; 10(507):. PubMed ID: 29184034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HMG-CoA reductase inhibitor fluvastatin prevents angiotensin II-induced cardiac hypertrophy via Rho kinase and inhibition of cyclin D1.
    Morikawa-Futamatsu K; Adachi S; Maejima Y; Tamamori-Adachi M; Suzuki J; Kitajima S; Ito H; Isobe M
    Life Sci; 2006 Aug; 79(14):1380-90. PubMed ID: 16712874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Statin-dependent activation of protein kinase Cδ in acute promyelocytic leukemia cells and induction of leukemic cell differentiation.
    Sassano A; Altman JK; Gordon LI; Platanias LC
    Leuk Lymphoma; 2012 Sep; 53(9):1779-84. PubMed ID: 22356114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Fluvastatin induces apoptosis on human tongue carcinoma cell line HSC-3].
    Fujiwara K; Tsubaki M; Yamazoe Y; Nishiura S; Kawaguchi T; Ogaki M; Nishinobo M; Shimamoto K; Moriyama K; Nishida S
    Yakugaku Zasshi; 2008 Jan; 128(1):153-8. PubMed ID: 18176067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An EGFR-Induced
    Bossen J; Uliczka K; Steen L; Pfefferkorn R; Mai MM; Burkhardt L; Spohn M; Bruchhaus I; Fink C; Heine H; Roeder T
    Mol Cancer Ther; 2019 Sep; 18(9):1659-1668. PubMed ID: 31217165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumour efficacy of the selumetinib and trametinib MEK inhibitors in a combined human airway-tumour-stroma lung cancer model.
    Mas C; Boda B; CaulFuty M; Huang S; Wiszniewski L; Constant S
    J Biotechnol; 2015 Jul; 205():111-9. PubMed ID: 25615947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unbiased in vivo preclinical evaluation of anticancer drugs identifies effective therapy for the treatment of pancreatic adenocarcinoma.
    Grbovic-Huezo O; Pitter KL; Lecomte N; Saglimbeni J; Askan G; Holm M; Melchor JP; Chandwani R; Joshi S; Haglund C; Iacobuzio-Donahue CA; Chiosis G; Tammela T; Leach SD
    Proc Natl Acad Sci U S A; 2020 Dec; 117(48):30670-30678. PubMed ID: 33199632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical activity of EGFR and MEK1/2 inhibitors in the treatment of biliary tract carcinoma.
    Cavalloni G; Peraldo-Neia C; Varamo C; Chiorino G; Sassi F; Aglietta M; Leone F
    Oncotarget; 2016 Aug; 7(32):52354-52363. PubMed ID: 27429047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trametinib (GSK1120212).
    Zeiser R; Andrlová H; Meiss F
    Recent Results Cancer Res; 2018; 211():91-100. PubMed ID: 30069762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identifying molecular features that distinguish fluvastatin-sensitive breast tumor cells.
    Goard CA; Chan-Seng-Yue M; Mullen PJ; Quiroga AD; Wasylishen AR; Clendening JW; Sendorek DH; Haider S; Lehner R; Boutros PC; Penn LZ
    Breast Cancer Res Treat; 2014 Jan; 143(2):301-12. PubMed ID: 24337703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of an "Exceptional Responder" Cell Line to MEK1 Inhibition: Clinical Implications for MEK-Targeted Therapy.
    Gannon HS; Kaplan N; Tsherniak A; Vazquez F; Weir BA; Hahn WC; Meyerson M
    Mol Cancer Res; 2016 Feb; 14(2):207-15. PubMed ID: 26582713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In-vitro synergism of m-TOR inhibitors, statins, and classical chemotherapy: potential implications in acute leukemia.
    Calabro A; Tai J; Allen SL; Budman DR
    Anticancer Drugs; 2008 Aug; 19(7):705-12. PubMed ID: 18594212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sorafenib and fluvastatin synergistically alleviate hepatic fibrosis via inhibiting the TGFβ1/Smad3 pathway.
    Cheng Y; Zheng H; Wang B; Xu W; Xu J; Zhu Y
    Dig Liver Dis; 2018 Apr; 50(4):381-388. PubMed ID: 29373239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.